unknown
Stage
1
Investors
About
Abiologics leverages artificial intelligence and chemical protein synthesis to create a new class of supranatural and programmable biologics called Synteins™, aimed at revolutionizing therapeutics across oncology, immunology, and metabolic diseases.
Explore Abiologics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.